High-density lipoprotein-mediated cardioprotection in heart failure

Jackson, Ampadu O.; Meng, Jun; Tang, Huifang; Yin, Kai

doi:10.1007/s10741-020-09916-0

Cited by 11 publications

(6 citation statements)

References 137 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Even no previous evidence has indicated the associations between MHR and HF, as its’ components, monocytes and HDL-C have been broadly discussed in HF. 33 , 34 Considered previous studies have proved that MHR was an independent prognostic marker for patients with malignant tumors and myocardial infarction, we wondered whether MHR was a potential diagnostic indicator for CHF. 35 , 36 As a result, MHR proved to be a novel diagnostic indicator with an AUC value of 0.673 (95% CI 0.638‒0.706, p < 0.001), which is the first time.…”

Section: Discussionmentioning

confidence: 99%

Associations of systemic inflammatory markers with the risks of chronic heart failure: A case-control study

Liu

et al. 2022

Clinics

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Associations of systemic inflammatory markers with the risks of chronic heart failure: A case-control study

Liu

et al. 2022

Clinics

View full text Add to dashboard Cite

“…It can transport the excess cholesterol in the blood to the liver, process and decompose it into cholic acid salts, and excrete it through the bile duct, thus forming a special way of blood lipid metabolism. It can enhance the ability of blood lipid metabolism and keep the blood vessels unblocked [ 29 , 30 ]. Our results indicated that HDL of SC was significantly lower than BD/MDD/HC, which was related to the use of antipsychotic drugs [ 31 , 32 ].…”

Section: Discussionmentioning

confidence: 99%

Abnormal blood lipid and electrocardiogram characteristics in common mental disorders

Tang

et al. 2023

BMC Psychiatry

View full text Add to dashboard Cite

Background At present, there is not enough evidence to prove the relationship between blood lipid and electrocardiogram (ECG) abnormalities in common mental disorders (CMD). This study aimed to explore the relationship between them, to detect and prevent arrhythmia or sudden death. Methods We collected 272 CMD patients (maintained a fixed drug dose pattern for 1 year or more), including 95 schizophrenias (SC), 90 bipolar disorders (BD) and 87 major depressive disorders (MDD), and 78 healthy controls (HC) from the Third People’s Hospital of Foshan, China. We analyzed and compared their blood lipid and ECG indicators, to clarify the relationship between them. Results 350 participants were included. There were no significant differences in age, gender, total cholesterol (TC), low density lipoprotein (LDL) and QTc (p > 0.05) among subjects. And there were significant differences in body mass index (BMI), triglyceride (TG), high density lipoprotein (HDL), heart rate, PR interval and QRS width (p < 0.05). Person correlation analysis showed that QRS width was positively correlated with BMI and TG. And negatively correlated with HDL. Meanwhile, QTc was positively correlated with BMI. Multiple linear regional analysis further proved that TG (B = 3.849, p = 0.007) and LDL (B = 11.764, p = 0.018) were the risk factors, and HDL (B = -9.935, p = 0.025) was the protective factor for QRS width increase. Conclusion Long term medication of CMD patients should strengthen weight management, and conduct regular blood lipid and ECG examinations to achieve early detection and intervention in order to promote their health.

show abstract

“…Reduction of cholesterol levels by roxadustat may be partly mediated by the degradation of 3-hydroxy-3-methylglutaryl coenzyme A reductase [35], which is a rate-limiting enzyme in cholesterol synthesis [36]. Notably, the high-density lipoprotein levels were signi cantly lower than baseline at week 24 in the roxadustat group, possibly increasing the risk of cardiovascular disease in PD patients [37].…”

Section: Discussionmentioning

confidence: 99%

Effect of roxadustat on iron metabolism in patients with peritoneal dialysis: A real- world 24-week study

Zhang,

Jia,

Zheng

et al. 2023

Preprint

View full text Add to dashboard Cite

Background Roxadustat is an oral hypoxy inducing factor-prolyl hydroxylase inhibitor (HIF-PHI) that regulates iron metabolism in patients with chronic kidney disease (CKD) primarily by reducing hepcidin levels and mobilizing internal iron stores. More data are needed to demonstrate the efficacy of roxadustat in regulating iron metabolism in patients with peritoneal dialysis (PD) compared with erythropoiesis stimulating agents (ESAs). Methods This prospective cohort study enrolled PD patients with a mean hemoglobin level of 60 to 100 g/L. All subjects were randomized into two groups at a ratio of 2:1: the roxadustat group (106 cases), and the ESA group (53 cases). The primary endpoint was the change in the iron biomarker levels and the proportion of patients with absolute iron deficiency and functional iron deficiency. Results Compared with ESAs, roxadustat significantly decreased hepcidin level (difference,-20.09ng/mL; 95% CI, -30.26 to -9.92), attenuated the increase in serum soluble transferrin receptor (sTFR) level (difference, -7.87 nmol/L; 95% CI, -12.11 to -3.64), and reduced the proportion of patients with functional iron deficiency (roxadustat, 11.43%; ESA, 33.33%). There was no significant difference in safety of the two groups over the duration of the study. Conclusions Compared with ESA group, roxadustat group showed significant difffferences in all iron biomarker levels except serum ferritin (sFt) and transferrin saturation (TSAT). These results suggest that roxadustat was superior to ESAs as a therapy for iron metabolism in PD patients. Trial registration: This study completed Chinese Clinical Trial Registration on March 4,2022 (registration number: ChiCTR2200057231).

show abstract

High-density lipoprotein-mediated cardioprotection in heart failure

Cited by 11 publications

References 137 publications

Associations of systemic inflammatory markers with the risks of chronic heart failure: A case-control study

Associations of systemic inflammatory markers with the risks of chronic heart failure: A case-control study

Abnormal blood lipid and electrocardiogram characteristics in common mental disorders

Effect of roxadustat on iron metabolism in patients with peritoneal dialysis: A real- world 24-week study

Contact Info

Product

Resources

About